Kairos Pharma Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer

Kairos Pharma Ltd. reported positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 in men with metastatic castration-resistant prostate cancer. The clinical-stage biopharmaceutical company presented findings at the European Society for Medical Oncology meeting in Berlin showing that 86% of patients treated with ENV-105 combined with apalutamide experienced clinical benefit. All responding patients remained progression-free for at least four months, with half maintaining this status beyond one year.

The study demonstrated significant therapeutic potential with seven of nine evaluable patients experiencing PSA reductions, supporting the therapy's ability to restore hormone responsiveness in advanced prostate cancer patients. The randomized trial, conducted in collaboration with Cedars-Sinai and partner institutions, continues to enroll additional patients to further evaluate safety profiles and long-term efficacy outcomes. These interim results suggest ENV-105 could address critical unmet medical needs in prostate cancer treatment where resistance to standard therapies often develops.

ENV-105 represents an innovative approach to cancer therapeutics as an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. The elevation of CD105 in response to standard therapy frequently results in resistance and disease relapse. By specifically targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. The current Phase 2 trial for castrate-resistant prostate cancer builds on earlier research showing the compound's potential in overcoming treatment barriers.

The positive interim data position ENV-105 as a promising candidate in the oncology therapeutic landscape, particularly for patients who have developed resistance to existing treatments. The continued enrollment in the Phase 2 trial will provide additional data on the compound's safety profile and long-term efficacy. For more information about the company's developments, visit https://ibn.fm/KAPA. The full details of the clinical findings and ongoing research efforts continue to generate interest within the medical community focused on advancing cancer treatment options.